Loading
A way of classifying cancers at the junction of the oesophagus and stomach by where their centre sits, which decides whether they are treated as oesophageal or gastric.
The Siewert classification sorts adenocarcinomas of the gastro-oesophageal junction by where the centre of the tumour lies relative to the junction, which decides whether the cancer is managed as oesophageal or gastric. Type I tumours, centred 1 to 5 cm above the junction, are treated as oesophageal adenocarcinoma with regimens such as CROSS or FLOT. Type II tumours, from 1 cm above to 2 cm below, may be treated either way, and type III tumours, 2 to 5 cm below, are treated as gastric cancer with perioperative FLOT with or without durvalumab. The distinction matters for trial eligibility and surgical approach. Readers meet it in the gastric and oesophageal cancer records and in the term contrasting squamous cell carcinoma with adenocarcinoma of the oesophagus.
Squamous cancers sit in the upper and middle oesophagus, adenocarcinomas at the junction and in the stomach; the stomach wall also gives rise to GIST from its pacemaker cells.
Same organ: HER2-positive gastric cancer, Claudin 18.2-positive gastric cancer, PD-L1-high gastric cancer, Microsatellite-unstable (MSI-high) gastric cancer, Early gastric cancer, Oesophageal squamous cell carcinoma, Oesophageal and junctional adenocarcinoma, Oesophageal cancer, Gastrointestinal stromal tumour (GIST), KIT exon 11-mutant GIST, PDGFRA D842V-mutant GIST, Imatinib-resistant GIST
Showing the organ this term concerns: Gastric & gastro-oesophageal junction cancer.